-
公开(公告)号：EP4279128A2
公开(公告)日：2023-11-22
申请号：EP23196718.3
申请日：2015-12-29
发明人： KIM, Dong-Sik , LEE, Mi Jung , PARK, Jae Chan , LEE, Sumin , KWAK, Heechun , HWANG, SungHo , LIM, Hyung-Kwon , KIM, Kisu , PARK, Young Seoub , JEONG, Junhong , CHO, Ki Joon
IPC分类号： A61P7/04
摘要： The present invention relates to an antibody that binds specifically to a tissue factor pathway inhibitor (TFPI), a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell transformed with the vector, a method for producing the antibody, and a pharmaceutical composition for treating hemophilia, which comprises the antibody as an active ingredient. The antibody of the present invention, which binds specifically to TFPI, can activate the extrinsic pathway of blood coagulation by inhibiting TFPI. Thus, the antibody of the present invention can be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease in hemophilia-A or hemophilia-B patients.
-
2.发明公开
公开(公告)号：EP3262075A1
公开(公告)日：2018-01-03
申请号：EP15883495.2
申请日：2015-12-29
发明人： KIM, Dong-Sik , LEE, Mi Jung , PARK, Jae Chan , LEE, Sumin , KWAK, Heechun , HWANG, SungHo , LIM, Hyung-Kwon , KIM, Kisu , PARK, Young Seoub , JEONG, Junhong , CHO, Ki Joon
IPC分类号： C07K16/36 , C12N15/63 , A61K39/395 , A61P7/04
CPC分类号： C07K16/38 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/622 , C07K2317/72 , C07K2317/92
摘要： The present invention relates to an antibody that binds specifically to a tissue factor pathway inhibitor (TFPI), a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell transformed with the vector, a method for producing the antibody, and a pharmaceutical composition for treating hemophilia, which comprises the antibody as an active ingredient. The antibody of the present invention, which binds specifically to TFPI, can activate the extrinsic pathway of blood coagulation by inhibiting TFPI. Thus, the antibody of the present invention can be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease in hemophilia-A or hemophilia-B patients.
-
公开(公告)号：EP4279128A3
公开(公告)日：2024-02-28
申请号：EP23196718.3
申请日：2015-12-29
发明人： KIM, Dong-Sik , LEE, Mi Jung , PARK, Jae Chan , LEE, Sumin , KWAK, Heechun , HWANG, SungHo , LIM, Hyung-Kwon , KIM, Kisu , PARK, Young Seoub , JEONG, Junhong , CHO, Ki Joon
IPC分类号： C07K16/38 , C12N15/63 , A61K39/395 , A61P7/04 , A61P7/00
摘要： The present invention relates to an antibody that binds specifically to a tissue factor pathway inhibitor (TFPI), a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell transformed with the vector, a method for producing the antibody, and a pharmaceutical composition for treating hemophilia, which comprises the antibody as an active ingredient. The antibody of the present invention, which binds specifically to TFPI, can activate the extrinsic pathway of blood coagulation by inhibiting TFPI. Thus, the antibody of the present invention can be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease in hemophilia-A or hemophilia-B patients.
-
公开(公告)号：EP3875483A1
公开(公告)日：2021-09-08
申请号：EP19877066.1
申请日：2019-10-18
发明人： CHO, Ki Joon , LEE, Mijung , SONG, Eun Jung , KIM, Ki Su , KANG, Kwan Yub , CHO, Eui Cheol
摘要： The present invention relates to an asymmetric fusion protein in which a fragment of an antibody binding to an insulin receptor, an IDS enzyme, and an Fc region are fused, and a use thereof. The fusion protein can cross the blood-brain barrier (BBB) to deliver the IDS enzyme to the brain. Therefore, a pharmaceutical composition comprising the fusion protein as an active ingredient can be used as a therapeutic agent for a central nervous system disease and particularly, is expected to prevent and treat various diseases caused by ribosome accumulation.
-
-
-
搜索结果
4 条记录 (耗时 0.01 秒)
